Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Gibert J, Clavé S, Hardy-Werbin M, Taus Á, Rocha P, Longarón R, Piquer G, Chaib I, Carcereny E, Morán T, Salido M, Dalmases A, Bellosillo B, Arriola E. Gibert J, et al. Among authors: hardy werbin m. Lung Cancer. 2020 Feb;140:42-45. doi: 10.1016/j.lungcan.2019.12.003. Epub 2019 Dec 5. Lung Cancer. 2020. PMID: 31862576
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.
Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E. Hardy-Werbin M, et al. Oncoimmunology. 2017 Nov 27;7(2):e1395125. doi: 10.1080/2162402X.2017.1395125. eCollection 2018. Oncoimmunology. 2017. PMID: 29308329 Free PMC article.
Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.
Taus Á, Camacho L, Rocha P, Hardy-Werbin M, Pijuan L, Piquer G, López E, Dalmases A, Longarón R, Clavé S, Salido M, Albanell J, Bellosillo B, Arriola E. Taus Á, et al. Clin Lung Cancer. 2018 Sep;19(5):387-394.e2. doi: 10.1016/j.cllc.2018.03.015. Epub 2018 Mar 23. Clin Lung Cancer. 2018. PMID: 29656868 Clinical Trial.
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.
Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E. Hardy-Werbin M, et al. Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019. Oncoimmunology. 2019. PMID: 31069160 Free PMC article.
Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.
Taus Á, Camacho L, Rocha P, Hernández A, Longarón R, Clavé S, Fernández-Ibarrondo L, Salido M, Hardy-Werbin M, Fernández-Rodríguez C, Albanell J, Bellosillo B, Arriola E. Taus Á, et al. Among authors: hardy werbin m. Arch Bronconeumol (Engl Ed). 2021 May;57(5):323-329. doi: 10.1016/j.arbres.2020.01.023. Epub 2020 Apr 3. Arch Bronconeumol (Engl Ed). 2021. PMID: 32253118 English, Spanish.
Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
Rocha P, Ramal D, Ripoll E, Moliner L, Corbera A, Hardy-Werbin M, Orrillo M, Taus Á, Zuccarino F, Gibert J, Perera-Bel J, Casadevall D, Arriola E. Rocha P, et al. Among authors: hardy werbin m. JTO Clin Res Rep. 2020 Oct 28;2(1):100115. doi: 10.1016/j.jtocrr.2020.100115. eCollection 2021 Jan. JTO Clin Res Rep. 2020. PMID: 34589976 Free PMC article.
MultiCOVID: a multi modal deep learning approach for COVID-19 diagnosis.
Hardy-Werbin M, Maiques JM, Busto M, Cirera I, Aguirre A, Garcia-Gisbert N, Zuccarino F, Carbullanca S, Del Carpio LA, Ramal D, Gayete Á, Martínez-Roldan J, Marquez-Colome A, Bellosillo B, Gibert J. Hardy-Werbin M, et al. Sci Rep. 2023 Oct 31;13(1):18761. doi: 10.1038/s41598-023-46126-8. Sci Rep. 2023. PMID: 37907750 Free PMC article.
15 results